SCHEMBL9924083

SCHEMBL9924083

O=C(/N=C(/Nc1cc(F)cc(Cl)c1)NC1CCC(NC(=O)c2ccccc2)CC1)c1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GRM5 P41594 2/20 0.42
MC5R P33032 1/20 0.42
CRHR1 P34998 1/20 0.41
SMYD3 Q9H7B4 1/20 0.41
MCHR1 Q99705 3/20 0.41
SLC6A12 P48065 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
TP53 P04637 2/20 0.40
MDM2 Q00987 2/20 0.40
GRM4 Q14833 1/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
CCR3 P51677 1/20 0.39
HTR2B P41595 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9924333 0.97 NPC1 (0.44) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL9924071 0.93 KMT2A (0.43) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL9924457 0.92 NPC1 (0.43) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL9924330 0.91 GRM5 (0.47) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL9924215 0.88 SLC6A9 (0.41) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL9924258 0.86 GRM5 (0.47) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL9924070 0.86 GRM4 (0.40) MEN1KMT2ACRHR1GRM4
SCHEMBL9924090 0.85 APOB (0.40) MEN1KMT2ASMN1; SMN2MC5RTP53
SCHEMBL9924161 0.84 MCHR1 (0.37) MEN1KMT2ASMN1; SMN2MC5RMCHR1
SCHEMBL9924077 0.83 GRM4 (0.38) KMT2ASMN1; SMN2CRHR1GRM4DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed